Articles tagged with Metastasis
LSUHSC researchers identify LKB1 and Nischarin as a functional duo that regulate breast cancer cell migration and tumor growth. The study provides insight into the molecular mechanisms of tumor suppressor genes.
A team of researchers at Baylor College of Medicine has identified a signature of biomarkers that identifies circulating breast tumor cells destined to seed the brain with deadly cancer. The study shows limitations of current platforms used to identify cancer in this way, but also offers new hope for diagnosis and treatment.
Research at the University of Colorado Anschutz Medical Campus reveals that hsa-miR-146a is overexpressed in most metastatic bladder cancer tumors. This tiny miRNA molecule plays a crucial role in making bladder cancer more aggressive.
Research reveals Six2 homeoprotein promotes detachment of breast cancer cells from tissues, enabling their survival through the bloodstream and colonization at distant sites. Higher Six2 expression in human breast cancer tissues is associated with aggressive metastasis.
A novel protein governing metastasis and chemoresistance in pediatric osteosarcoma has been discovered using K9 osteosarcoma samples. The IGF2BP1 protein's overexpression is linked to aggressive disease progression, offering a potential target for treatment.
A Phase III clinical trial found that adding cetuximab to chemotherapy enables previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis. The combination also extends median overall survival by 10 months compared to chemotherapy alone.
Researchers have developed a non-invasive test for metastatic prostate cancer using whole-genome analysis of plasma DNA, which identifies abnormal copy numbers of specific sequences. This breakthrough could aid personalized therapy and target treatment for castration-resistant prostate cancer.
Researchers at Moffitt Cancer Center found that microRNA-155 overexpression promotes new blood vessel growth, tumor inflammation, and metastasis in breast cancer. Controlling miR-155 expression could inhibit malignant growth, providing a new avenue of treatment.
The CTC-iChip system rapidly produces a purified solution of tumor cells for pathological and molecular analysis. This technology enables the analysis of single metastatic cells, providing insights into cancer evolution and metastasis.
A CU Cancer Center study reveals that the transcription factor SPDEF regulates E-Cadherin production, inhibiting prostate cancer metastasis. The researchers found that increasing or decreasing SPDEF levels directly affects E-Cadherin expression, making it a crucial factor in preventing cancer spread.
Researchers at Sanford-Burnham Medical Research Institute discovered that the enzyme PKCζ acts as a tumor suppressor in both mice and humans, controlling cell growth and metastasis. Restoring PKCζ levels may provide a novel therapeutic target for treating prostate cancer.
Researchers at UNC have found that protein palladin enhances cancer-associated fibroblasts' ability to break down barriers and create pathways for tumors to spread. This discovery could lead to new treatments and screening options for pancreatic cancers.
Researchers have developed a multi-stage, multi-orifice flow fractionation system to detect and separate circulating tumor cells (CTCs) from blood with high efficiency, improving separation efficiency to 98.9%. The device, called MS-MOFF, employs hydrodynamic sorting and can collect viable CTCs after sorting.
A study by the ZEUS group found no significant difference in the incidence of bone metastases between patients receiving zoledronic acid and those on standard treatment. The 50-month study suggested that zoledronic acid may not be effective in preventing hormone therapy-induced bone loss in high-risk prostate cancer patients.
A large multicentre study found that small kidney tumours can have an aggressive potential and should be treated. The study included 2197 patients with RCC of 4 cm or smaller and showed that the risk of nodal disease or distant metastasis increased significantly with rising tumour diameter.
A study published in Science Signaling identified a critical protein role in the spread of melanoma to the lungs. Researchers found that inhibiting the adenosine diphosphate ribosylation factor 6 (ARF6) protein reduces melanoma metastasis.
Researchers at VCU Massey Cancer Center have developed a novel immunotherapy that could work like a vaccine against metastatic cancers. The therapy, called Flagrp-170, uses a molecule engineered to stimulate the immune system and attack cancer cells, with promising results in animal models.
Researchers found that patients with metastatic gastric cancer who underwent both surgery and radiation had better survival rates than those receiving one or no treatment. Radiation therapy also showed promise in reducing symptoms such as pain, obstruction, and bleeding from gastric tumors.
A recent study found a small but statistically significant increase in the incidence of advanced breast cancer among young women aged 25-39 years, without a corresponding increase in older women. This trend is concerning due to the poor prognosis and lower survival rates associated with younger patients.
Researchers at UH Cancer Center identify RSK2 protein as key player in cancer cell migration and metastasis. The discovery may lead to selective treatments targeting specific tumor types, improving treatment outcomes.
A meta-analysis found that increased fascin-1 is associated with increased risk of mortality in breast, colorectal, and oesophageal carcinomas. Fascin-1 was also linked to disease progression and metastasis in some cases, but not others.
Scientists have generated molecules that inhibit tumour cell adhesion to other cells, halting both tumour growth and liver metastasis. The breakthrough could lead to new treatments for colon cancer and its related death toll.
Researchers found that IQGAP1, a molecule controlling cell shape and movement, can suppress the growth of liver tumors when active in surrounding cells. The study provides new insight into cancer metastasis and points to potential therapeutic targets for preventing or treating liver metastases.
Researchers identified miR-7 as a metastasis suppressor that suppressed cancer stem-like cells' ability to metastasize to the brain. The miR-7/KLF4 axis played a critical role in cancer stem-like cell brain metastasis, suggesting its potential as a diagnostic or therapeutic target for predicting or treating brain metastases.
Researchers discovered that long non-coding RNA MALAT1 regulates genes involved in metastasis, leading to impaired mobility and tumor growth. By silencing MALAT1, the team found reduced metastasis formation in mice, opening a promising approach for lung cancer treatment.
Researchers associate epithelial-mesenchymal transition (EMT) with breast cancer disease progression and treatment response. EMT was detected in breast cancer patient samples and found to oscillate between epithelial and mesenchymal states, influencing tumor spread and invasiveness.
A genetically reprogrammed Herpes simplex virus has been engineered to target and kill cancer cells expressing the HER-2 oncogene, specifically breast and ovarian cancer metastases. This breakthrough oncolytic herpesvirus has shown promising results in treating experimental metastasis, holding promise for a novel type of cancer treatment.
Researchers at Georgia State University have identified a new target to stop cancer's spread, targeting the interaction between two proteins in cells. Disrupting this interaction inhibits metastasis and has implications for treating various diseases.
GATA3 acts downstream to activate microRNA29b, which stops tumor cells from spreading by inhibiting genes involved in metastasis. The absence of GATA3 allows cancerous cells to break free and induce inflammation and new blood vessel formation.
Researchers at BRIC, University of Copenhagen, have found that blocking the enzyme Lysyl Oxidase (LOX) can significantly decrease metastasis in breast cancer models. This breakthrough suggests a new approach to prevent tumour microenvironment scarring and enhance patient outcomes.
Breast cancer cells use pro-inflammatory signaling molecules to adhere to blood vessel surfaces, promoting metastasis. The Cornell researchers found that these cells are unable to interact with selectins, a key step in the process, and that inflammatory molecules enable them to adhere.
Researchers discovered stable epigenetic marks across all metastatic tumors in each patient, defying the idea that these marks vary greatly within individuals. These consistent methylation changes appear to represent driver changes critical to cancer development and could be targets for treatment.
Researchers discovered that grape seed extract selectively targets advanced colorectal cancer cells with fewer genetic mutations, leading to increased effectiveness in treatment. The compound induces oxidative stress and programmed cell death, reversing its effects when antioxidants are present.
A University of Colorado Cancer Center study found that SPARC acts as an anti-inflammatory drug, reducing tumor growth and metastasis in bladder cancer. The protein is produced by healthy tissue to mute tumors, but aggressive cancers suppress its production, leading to faster disease progression.
The hepatitis B virus X protein (HBx) represses microRNA-148a, leading to increased levels of the oncogenic protein HPIP and subsequent oncogenic transformation in liver cancer. This study demonstrates a cancer-associated virus promoting carcinogenesis through direct manipulation of a microRNA.
A Weill Cornell study reveals that a specific miRNA, miR-708, acts as a metastatic tumor inhibitor and can be restored to stop the spread of aggressive breast cancer. Synthetic miR-708 delivery has blocked metastatic outgrowth in mice, making it a promising therapeutic target.
Researchers at Fox Chase Cancer Center found that the NEDD9 gene controls the growth of progenitor cells that give rise to tumors, suggesting a new approach to treating breast cancer. The study also identified a link between NEDD9 levels and sensitivity to certain drugs.
Dr. Nicholas Navin's new approach to genetic analysis could help researchers understand and map the complex process of cancer evolution, ultimately blocking the spread of cancer to other organs. The project aims to identify important mutations in single tumor cells at various stages of cancer development.
A study of 722 patients found that those taking beta-blockers for other conditions lived longer after receiving radiotherapy. The use of beta-blockers improved survival rates without disease spreading or recurring, but not locoregional progression-free survival.
The Damon Runyon-Rachleff Innovation Award funds cancer research by exceptionally creative thinkers with 'high-risk/high-reward' ideas, selected through a rigorous process. Seven awardees aim to develop new approaches to fighting cancer, including virus-based treatments and single-cell sequencing tools.
Researchers at Virginia Commonwealth University discovered that gene mda-9/syntenin regulates angiogenesis, a process responsible for forming new blood vessels in tumors. IGFBP-2, found to be elevated in most cancers, may serve as a novel biomarker for disease progression.
Thomas Jefferson University researchers have identified new pathways that drive aggressive forms of prostate cancer. Elevated levels of Cyclin D1b function as a novel biomarker for lethal metastatic disease in prostate cancer patients.
Researchers identified ID proteins as regulators of glioma progression and potential therapeutic targets. In contrast, the loss of TREM-1 increased inflammation and worsened lung infection outcomes in mice. Additionally, breast cancer cells interact with stroma to drive metastasis through HIF-dependent signaling pathways.
Researchers have discovered a new therapy combination that targets the PI3K and JAK2/STAT5 pathways to combat aggressive metastatic breast cancer. In mouse studies, this approach led to slower tumor growth, reduced spread, and improved survival rates.
A study by Dr. George M Yousef at St. Michael's Hospital identified 29 proteins associated with kidney tumor metastasis. These biomarkers can help physicians recognize which tumors are more likely to spread, enabling targeted treatment and improved patient outcomes.
Researchers at University of California, San Diego School of Medicine discovered the reversible EMT switch in metastasis, resolving a decade-long debate. Activation of Twist1 gene promotes carcinoma cells to disseminate into blood circulation, while turning off EMT switch is crucial for proliferation and formation of secondary tumors.
Researchers found that high levels of COUP-TFII can overcome a natural barrier to prostate cancer progression, allowing tumor cells to grow and spread throughout the body. The study suggests that COUP-TFII is an important 'second hit' for the progression of prostate cancer and metastasis.
A cost-effectiveness analysis found that KRAS testing is cost-saving, while BRAF testing offers additional savings. The study suggests that molecular testing primarily generates cost savings by identifying nonresponders, rather than improving survival.
Researchers identified a group of microRNAs that work together to suppress the spread of cancer by repressing epithelial-to-mesenchymal transition. This discovery offers potential therapeutic targets and diagnostic tools for predicting and inhibiting cancer metastasis.
Dr. Debra Auguste aims to develop targeted treatments for four metastatic breast cancer populations using engineered liposomes that deliver short interfering RNA to inhibit tumor progression and metastasis. The goal is to enhance cooperative binding, reduce cell migration, and improve treatment efficacy.
Researchers at the University of Copenhagen have discovered that a protein known for causing cancer cells to spread is also involved in brain repair. The study, published in Nature Communications, suggests new avenues for treating degenerative brain diseases like Alzheimer's.
A study published in the Journal of Thoracic Oncology found that denosumab was associated with significantly improved overall median survival in lung cancer patients, including those with non-small-cell lung cancer and small-cell lung cancer. The treatment also showed improved survival in patients with squamous cell carcinoma.
A new gene delivery vehicle has been developed to target tumor cells with the TNFα cytokine, allowing for improved drug delivery and reduced resistance. The treatment approach combines the cytokine with a DNA-intercalating drug doxorubicin, showing promise in reducing tumor growth and metastasis.
Scientists at Virginia Commonwealth University have made a significant breakthrough in understanding how cancer spreads, discovering that a specific protein can be inhibited to stop melanoma metastasis. The research could lead to new targeted therapies and diagnostic tools for patients with melanoma and potentially other cancers.
A team of researchers found that tumour cells form alliances with surrounding healthy cells, called stroma, to colonize other organs during metastasis. This discovery could lead to a test to predict relapse and tailored treatment regimes for patients.
A combination of an anti-HER2 drug and an angiogenesis inhibitor significantly improves survival in a mouse model of brain metastatic breast cancer. The treatment extends patient survival by slowing the growth of brain tumors, making it a promising approach for patients with HER2-positive breast cancer who develop brain metastases.
Researchers developed a diagnostic tool identifying breast cancer cells' ability to spread, based on their lipid profile. The technique, Raman microspectroscopy, has shown promise for routine cytological diagnosis and may be extended to other tumors.
Researchers found that genetic imbalances in most cases determine the evolution from noninvasive to invasive disease. The study identified patterns consistent with known aberration profiles for breast cancer, including the loss of tumor suppressor CDH1 and gain of oncogene MYC.
Breast tumor cells interact with mesenchymal stem cells (MSCs) in the tumor microenvironment, triggering production of lysyl oxidase (LOX), a gene that enables cell migration and metastasis. This process, called epithelial-to-mesenchymal transition (EMT), allows cancer cells to spread to bones and other parts of the body.
A new MIT study reveals cellular adhesion molecules critical to cancer's metastasis, offering potential new targets for cancer drug therapy. The researchers found that adhesion tendencies of metastatic cells from different primary tumors were similar, suggesting a shared pathway.